WEBVTT 00:00:00.000 --> 00:00:04.139 Welcome to the very first deep dive. It's pretty 00:00:04.139 --> 00:00:06.339 exciting. Yeah, it is. You know, it's amazing 00:00:06.339 --> 00:00:09.939 to think that every medicine we rely on, every 00:00:09.939 --> 00:00:13.660 pill or injection, started as just an idea. Crazy. 00:00:13.839 --> 00:00:17.600 Right? Today we are diving deep into the incredible 00:00:17.600 --> 00:00:21.339 journey of drug development, how that initial 00:00:21.339 --> 00:00:25.280 spark of scientific inspiration transforms into 00:00:25.280 --> 00:00:27.239 a treatment available at your local pharmacy. 00:00:27.960 --> 00:00:30.660 It's really quite a process. What's fascinating 00:00:30.660 --> 00:00:33.359 is that this journey isn't a quick sprint. It's 00:00:33.359 --> 00:00:36.140 more like an ultra marathon. Wow. We're talking 00:00:36.140 --> 00:00:39.140 about a process that takes 10 to 15 years. OK. 00:00:39.560 --> 00:00:42.840 Sometimes even longer. Oh, wow. And costs. Hundreds 00:00:42.840 --> 00:00:45.380 of millions, even billions of dollars. That's 00:00:45.380 --> 00:00:47.979 a serious commitment of time and resources. It 00:00:47.979 --> 00:00:50.219 makes you wonder why it takes so long and why 00:00:50.219 --> 00:00:52.640 it's so expensive. I mean, we can put a human 00:00:52.640 --> 00:00:54.640 on the moon faster than we can develop a new 00:00:54.640 --> 00:00:58.100 drug. Well, you have to remember, we're not launching 00:00:58.100 --> 00:01:01.479 a rocket. We're introducing new substances into 00:01:01.479 --> 00:01:04.579 the human body. Of course. The stakes are incredibly 00:01:04.579 --> 00:01:07.680 high. Yeah. We need absolute certainty. Right. 00:01:07.920 --> 00:01:10.459 That a new treatment is both safe and effective 00:01:10.459 --> 00:01:12.540 before it reaches patients. That makes sense. 00:01:12.700 --> 00:01:14.599 There's simply no room for shortcuts when it 00:01:14.599 --> 00:01:17.280 comes to human health. I get it. So safety and 00:01:17.280 --> 00:01:20.500 efficacy are paramount. Absolutely. OK, so let's 00:01:20.500 --> 00:01:22.319 break down this marathon, shall we? Sure. What 00:01:22.319 --> 00:01:25.579 are the major stages of drug development? So 00:01:25.579 --> 00:01:27.680 broadly speaking, the journey can be divided 00:01:27.680 --> 00:01:31.540 into five key stages. OK. Discovery. pre -clinical 00:01:31.540 --> 00:01:35.159 research, clinical trials, regulatory review, 00:01:35.799 --> 00:01:38.000 and post -marketing surveillance. Okay, five 00:01:38.000 --> 00:01:40.500 stages. Yeah. It sounds almost manageable when 00:01:40.500 --> 00:01:42.739 you put it like that. Right. But I have a feeling 00:01:42.739 --> 00:01:44.980 each stage is packed with complexity. Oh, you're 00:01:44.980 --> 00:01:47.239 absolutely right. Okay. Let's start with the 00:01:47.239 --> 00:01:49.079 first stage discovery. All right. This is where 00:01:49.079 --> 00:01:53.040 it all begins. the spark of an idea. Scientists 00:01:53.040 --> 00:01:56.099 identify a disease they want to target and then 00:01:56.099 --> 00:01:59.200 zoom in, way in, to the molecular level to figure 00:01:59.200 --> 00:02:01.799 out what's going wrong. They're searching for 00:02:01.799 --> 00:02:04.120 the root cause, the target that needs to be fixed 00:02:04.120 --> 00:02:07.000 to restore health. So it's kind of like finding 00:02:07.000 --> 00:02:09.759 the glitch in a computer program. That's causing 00:02:09.759 --> 00:02:12.159 the whole system to crash. That's a great analogy. 00:02:12.800 --> 00:02:15.419 And once they've identified the target, the hunt 00:02:15.419 --> 00:02:17.900 begins for a molecule that can interact with 00:02:17.900 --> 00:02:20.900 it in a specific way. Imagine trying to find 00:02:20.900 --> 00:02:26.000 the perfect key for a tiny intricate lock. That 00:02:26.000 --> 00:02:29.740 key is our potential drug. Gotcha. So I can only 00:02:29.740 --> 00:02:31.699 imagine the number of keys they have to test 00:02:31.699 --> 00:02:35.150 before they find the right one. It's a lot. Yeah. 00:02:35.250 --> 00:02:37.990 So how do they even begin to narrow down the 00:02:37.990 --> 00:02:40.229 search? That's a good question. That takes us 00:02:40.229 --> 00:02:43.310 to the second sage preclinical research. OK. 00:02:43.650 --> 00:02:46.310 This is where scientists put those potential 00:02:46.310 --> 00:02:49.770 drug candidates through a rigorous series of 00:02:49.770 --> 00:02:52.509 tests. Right. But before they ever reach a human. 00:02:52.870 --> 00:02:55.289 So it's like a boot camp for drugs. Yes. Weeding 00:02:55.289 --> 00:02:57.349 out the week before they go into battle. Exactly. 00:02:57.789 --> 00:03:00.900 The first step is testing in the lab. Using cells 00:03:00.900 --> 00:03:03.000 and tissues to see if the drug actually works 00:03:03.000 --> 00:03:05.560 against the target. Does it bind to the lock? 00:03:06.139 --> 00:03:09.099 Does it produce the desired effect? And importantly, 00:03:09.280 --> 00:03:13.539 is it toxic to cells? Safety first, always. Yes. 00:03:13.840 --> 00:03:15.439 So it's a lot of trial and error, I imagine. 00:03:15.500 --> 00:03:18.180 It is. And if a drug candidate shows promise 00:03:18.180 --> 00:03:21.139 in these initial tests, it moves on to animal 00:03:21.139 --> 00:03:24.020 studies. This is where things get a bit more 00:03:24.020 --> 00:03:27.500 complex, ethically speaking. But it's a crucial 00:03:27.500 --> 00:03:31.139 step in understanding how a drug behaves in a 00:03:31.139 --> 00:03:33.780 living organism. I can see why animal studies 00:03:33.780 --> 00:03:36.500 would be a sensitive topic. Yeah. Can you talk 00:03:36.500 --> 00:03:38.280 a bit more about why they're necessary and how 00:03:38.280 --> 00:03:40.900 they're conducted? Of course. Right. Animal studies 00:03:40.900 --> 00:03:43.580 provide critical information about a drug's safety 00:03:43.580 --> 00:03:47.319 and effectiveness in a complex biological system. 00:03:47.340 --> 00:03:50.080 Right. We can observe how the drug is absorbed, 00:03:50.479 --> 00:03:52.800 distributed throughout the body, metabolized, 00:03:53.400 --> 00:03:55.759 and eventually eliminated. Right. Animal studies 00:03:55.759 --> 00:03:58.080 also allow us to determine safe and effective 00:03:58.080 --> 00:04:01.039 dosage ranges, something we can't ethically do 00:04:01.039 --> 00:04:03.939 in the initial stages of human testing. I see. 00:04:03.939 --> 00:04:07.319 So it's about minimizing risk as much as possible 00:04:07.319 --> 00:04:10.659 before moving to human trials. Precisely. Gotcha. 00:04:11.080 --> 00:04:14.120 And while there are always ethical considerations. 00:04:14.159 --> 00:04:16.500 Of course. These studies are conducted under 00:04:16.500 --> 00:04:19.500 strict regulations and oversight. Right. To ensure 00:04:19.500 --> 00:04:23.399 the humane treatment of animals. OK. It's a responsibility 00:04:23.399 --> 00:04:25.899 that scientists and research institutions take 00:04:25.899 --> 00:04:29.100 very seriously. OK. So let's imagine our drug 00:04:29.100 --> 00:04:32.220 candidate has successfully navigated this preclinical 00:04:32.220 --> 00:04:35.199 boot camp. Right. What happens next? Then it's 00:04:35.199 --> 00:04:38.180 time for the big leagues, human clinical trials. 00:04:38.839 --> 00:04:41.660 This is where we finally test the drug on humans 00:04:41.660 --> 00:04:45.689 in a very controlled and staged This is what 00:04:45.689 --> 00:04:47.550 we often hear about in the news, right? There's 00:04:47.550 --> 00:04:50.230 large -scale trials involving thousands of patients. 00:04:50.389 --> 00:04:53.730 Exactly. But before we get to those massive phase 00:04:53.730 --> 00:04:57.029 three trials, there are two earlier phases. Clinical 00:04:57.029 --> 00:04:59.730 trials are divided into three phases, each building 00:04:59.730 --> 00:05:02.470 on the previous one, and providing more and more 00:05:02.470 --> 00:05:05.029 data about the drug's safety and effectiveness. 00:05:05.490 --> 00:05:07.790 And this is one of the main reasons why drug 00:05:07.790 --> 00:05:10.829 development takes years. Makes sense. OK, break 00:05:10.829 --> 00:05:14.449 it down for us. What happens in each phase? So 00:05:14.449 --> 00:05:18.129 in phase one, safety is the absolute priority. 00:05:18.709 --> 00:05:22.160 We test the drug on a small group. of healthy 00:05:22.160 --> 00:05:25.420 volunteers, not patients with the disease, to 00:05:25.420 --> 00:05:29.040 assess its safety profile. We're looking at how 00:05:29.040 --> 00:05:31.920 it's processed in the body, how long it stays 00:05:31.920 --> 00:05:35.079 in the bloodstream, and what side effects, if 00:05:35.079 --> 00:05:36.860 any, it causes. So it's like dipping your toes 00:05:36.860 --> 00:05:39.300 in the water before jumping in the pool. Exactly. 00:05:39.519 --> 00:05:43.339 Then comes phase two, where we expand the trial 00:05:43.339 --> 00:05:45.720 to include patients who actually have the disease 00:05:45.720 --> 00:05:49.160 we're targeting. Now the focus shifts to determining 00:05:49.160 --> 00:05:51.319 if the drug is actually effective. in treating 00:05:51.319 --> 00:05:53.339 the condition. So does it work in the real world, 00:05:53.379 --> 00:05:56.360 not just in the lab? Precisely. And finally we 00:05:56.360 --> 00:05:59.600 have phase three. The large -scale trials you 00:05:59.600 --> 00:06:02.819 mentioned, these trials often involve thousands 00:06:02.819 --> 00:06:07.040 of patients across multiple locations. And they 00:06:07.040 --> 00:06:10.360 compare the new drug to existing treatments or... 00:06:10.540 --> 00:06:14.620 a placebo. Phase three trials are the gold standard 00:06:14.620 --> 00:06:17.339 for gathering evidence about a drug's effectiveness 00:06:17.339 --> 00:06:20.699 and long -term safety. So it sounds like a really 00:06:20.699 --> 00:06:23.620 rigorous stepwise approach. It is. With each 00:06:23.620 --> 00:06:26.660 phase adding another layer of certainty. But 00:06:26.660 --> 00:06:28.160 I'm guessing the journey doesn't end there, does 00:06:28.160 --> 00:06:30.819 it? You're absolutely right. Okay. Even if a 00:06:30.819 --> 00:06:34.600 drug shows promise in all three phases of clinical 00:06:34.600 --> 00:06:38.319 trials, it still faces another hurdle. Oh, what's 00:06:38.319 --> 00:06:40.579 that? Regulatory review. In the U .S., that would 00:06:40.579 --> 00:06:42.740 be the Food and Drug Administration or FDA, right? 00:06:42.800 --> 00:06:45.740 That's correct. The FDA or similar agencies in 00:06:45.740 --> 00:06:49.509 other countries play a crucial role. in protecting 00:06:49.509 --> 00:06:52.370 public health. They have the challenging task 00:06:52.370 --> 00:06:55.850 of reviewing all the data from those years of 00:06:55.850 --> 00:06:59.829 clinical trials, scrutinizing everything, safety 00:06:59.829 --> 00:07:03.029 efficacy manufacturing processes to ensure the 00:07:03.029 --> 00:07:04.529 drug meets the highest standards. That sounds 00:07:04.529 --> 00:07:06.790 like a pretty tough exam to pass. It is, and 00:07:06.790 --> 00:07:09.589 it should be. These agencies are responsible 00:07:09.589 --> 00:07:12.839 for making sure that the benefits of a new drug 00:07:12.839 --> 00:07:16.120 truly outweigh any potential risks. They ask 00:07:16.120 --> 00:07:19.019 the hard questions. Is the manufacturing process 00:07:19.019 --> 00:07:22.279 reliable? Are the labeling and instructions clear? 00:07:23.060 --> 00:07:25.399 Only after this thorough and independent review 00:07:25.399 --> 00:07:28.420 will a drug be approved for market? OK, so it's 00:07:28.420 --> 00:07:30.540 reassuring to know that there is such a rigorous 00:07:30.540 --> 00:07:32.740 system in place to protect patients. Definitely. 00:07:33.579 --> 00:07:36.860 So once a drug gets that regulatory stamp of 00:07:36.860 --> 00:07:39.779 approval, it's game on, right? It's finally ready 00:07:39.779 --> 00:07:42.379 to be prescribed and used. It's certainly a major 00:07:42.379 --> 00:07:45.300 milestone, but the journey isn't over yet. Oh, 00:07:45.300 --> 00:07:47.480 really? What else is there? There's one more 00:07:47.480 --> 00:07:50.560 crucial stage. Post -marketing surveillance. 00:07:50.879 --> 00:07:53.100 Post -marketing surveillance. OK, I'm intrigued. 00:07:53.620 --> 00:07:56.040 What does that involve? So even after a drug 00:07:56.040 --> 00:07:59.120 is on the market and being used by potentially 00:07:59.120 --> 00:08:02.019 millions of people, it's still under scrutiny. 00:08:02.189 --> 00:08:04.750 Interesting. Scientists and regulatory agencies 00:08:04.750 --> 00:08:07.930 continue to monitor the drug for long term effects, 00:08:07.949 --> 00:08:10.689 looking for any rare or delayed side effects 00:08:10.689 --> 00:08:13.589 that might not have emerged during clinical trials. 00:08:13.750 --> 00:08:15.810 Oh, so it's not a one time approval and then 00:08:15.810 --> 00:08:18.069 everyone just moves on? Not at all. OK. Drug 00:08:18.069 --> 00:08:21.810 development is a dynamic ongoing process. Right. 00:08:22.189 --> 00:08:25.750 New information about a drug's safety and efficacy 00:08:25.750 --> 00:08:29.970 can emerge over time. And the FDA continues to 00:08:29.970 --> 00:08:32.710 evaluate this information. Right. And can take 00:08:32.710 --> 00:08:35.990 action if needed. That's really reassuring. Yeah. 00:08:36.210 --> 00:08:38.809 So it's a constant process of learning, adapting, 00:08:39.610 --> 00:08:42.370 and ensuring the well -being of patients. Exactly. 00:08:42.649 --> 00:08:45.190 OK. This whole process is fascinating. It is. 00:08:45.610 --> 00:08:47.870 But before we move on, I'd love to know more 00:08:47.870 --> 00:08:49.909 about something that really caught my eye in 00:08:49.909 --> 00:08:52.289 the research. OK. The challenge of developing 00:08:52.289 --> 00:08:54.950 oral dosage forms. Right. I mean, swallowing 00:08:54.950 --> 00:08:57.629 a pill seems so simple. Yeah. But I'm realizing 00:08:57.629 --> 00:09:00.070 there's a lot more to it than meets the eye. 00:09:00.190 --> 00:09:02.669 You're absolutely right. Developing an effective 00:09:02.669 --> 00:09:06.429 oral dosage form is a science in itself. Just 00:09:06.429 --> 00:09:08.850 getting the drug into your body isn't enough. 00:09:09.070 --> 00:09:12.149 It needs to be absorbed properly to have the 00:09:12.149 --> 00:09:14.529 desired effect. And that's where the concept 00:09:14.529 --> 00:09:17.809 of bioavailability comes into play. Bioavailability, 00:09:17.909 --> 00:09:19.769 I remember reading about that. It's not just 00:09:19.769 --> 00:09:22.730 about how much drug is in the pill, but how much 00:09:22.730 --> 00:09:24.549 of it actually reaches the bloodstream where 00:09:24.549 --> 00:09:27.750 it can do its job. Exactly. Bioavailability is 00:09:27.750 --> 00:09:31.159 key. and it depends on a complex interplay of 00:09:31.159 --> 00:09:35.980 factors. The drug's solubility, its ability to 00:09:35.980 --> 00:09:39.080 pass through membranes, the formulation of the 00:09:39.080 --> 00:09:41.799 pill itself, and even individual differences 00:09:41.799 --> 00:09:46.279 in how our bodies absorb and process drugs. Even 00:09:46.279 --> 00:09:49.980 if a drug is incredibly promising, a poorly designed 00:09:49.980 --> 00:09:52.740 pill could render it ineffective. That's right. 00:09:52.940 --> 00:09:55.799 Wow. And that's why pharmaceutical scientists 00:09:55.799 --> 00:09:58.440 spend a great deal of time and effort in formulation 00:09:58.440 --> 00:10:02.179 development. They carefully select inactive ingredients 00:10:02.179 --> 00:10:06.059 called excipients to optimize the drug's release, 00:10:06.220 --> 00:10:09.820 absorption, and stability. Wow. I never realized 00:10:09.820 --> 00:10:12.419 there was so much science behind something as 00:10:12.419 --> 00:10:16.539 seemingly simple as swallowing a pill. It's a 00:10:16.539 --> 00:10:19.320 fascinating area of research, full of challenges 00:10:19.320 --> 00:10:21.500 and innovation. Well, this is all incredibly 00:10:21.500 --> 00:10:23.879 insightful. We've covered so much ground already, 00:10:24.139 --> 00:10:27.240 from the initial spark of an idea to the complex 00:10:27.240 --> 00:10:31.059 world of formulation and bioavailability. It's 00:10:31.059 --> 00:10:33.220 clear that bringing a new medicine to market 00:10:33.220 --> 00:10:36.740 is an incredible feat of scientific collaboration 00:10:36.740 --> 00:10:40.500 and perseverance. Absolutely. So thank you. You're 00:10:40.500 --> 00:10:42.779 welcome. You know what's truly remarkable about 00:10:42.779 --> 00:10:45.440 oral dosage forms is how they bridge the gap 00:10:45.440 --> 00:10:48.919 between scientific discovery and the patient 00:10:48.919 --> 00:10:51.759 experience. I see. It's not just about the active 00:10:51.759 --> 00:10:54.740 ingredient itself. It's about creating a delivery 00:10:54.740 --> 00:10:57.580 system that works in harmony with the body. That 00:10:57.580 --> 00:11:00.159 makes a lot of sense. Yeah. So formulation scientists 00:11:00.159 --> 00:11:02.399 are like the master chefs of drug development. 00:11:02.399 --> 00:11:05.019 That's a great analogy. Carefully blending ingredients 00:11:05.019 --> 00:11:08.080 to create the perfect recipe. Exactly. And just 00:11:08.080 --> 00:11:11.200 like a master chef considers flavor texture in 00:11:11.200 --> 00:11:14.460 presentation, formulation scientists focus on 00:11:14.460 --> 00:11:17.259 factors like solubility stability and, of course, 00:11:17.559 --> 00:11:19.879 bioavailability. Right. They need to ensure the 00:11:19.879 --> 00:11:21.519 drug is delivered to the right place at the right 00:11:21.519 --> 00:11:24.220 time and in the right amount. And I imagine they 00:11:24.220 --> 00:11:26.139 also have to make sure the final product doesn't 00:11:26.139 --> 00:11:29.159 taste horrible. Absolutely. Nobody wants to dread 00:11:29.159 --> 00:11:31.500 taking their medicine. Patient compliance is 00:11:31.500 --> 00:11:34.700 a crucial consideration. Right. Especially for 00:11:34.700 --> 00:11:37.200 medications that need to be taken long term. 00:11:37.879 --> 00:11:40.559 A bitter pill, no matter how effective, won't 00:11:40.559 --> 00:11:43.019 do much good if the patient avoids taking it. 00:11:43.320 --> 00:11:45.500 That's true. So you mentioned dissolution studies 00:11:45.500 --> 00:11:47.379 earlier. Can you walk us through those? Sure. 00:11:47.480 --> 00:11:50.379 Why are they so crucial in this process? Dissolution 00:11:50.379 --> 00:11:53.120 studies are essentially like time -lapse photography, 00:11:53.659 --> 00:11:57.320 but for pills, we use specialized equipment to 00:11:57.320 --> 00:12:00.179 mimic the conditions in the digestive tract, 00:12:00.740 --> 00:12:03.200 the temperature, the pH, the churning motions, 00:12:03.220 --> 00:12:05.860 and we measure how quickly the drug dissolves 00:12:05.860 --> 00:12:07.899 from the pill over time. So it's like a window 00:12:07.899 --> 00:12:09.759 into how the pill breaks down in the stomach 00:12:09.759 --> 00:12:12.379 and intestine. Precisely. Okay, cool. And by 00:12:12.379 --> 00:12:15.580 analyzing the dissolution data, we can optimize 00:12:15.580 --> 00:12:18.779 the formulation to ensure the drug releases at 00:12:18.779 --> 00:12:21.529 the desired rate. whether that's a quick burst 00:12:21.529 --> 00:12:25.610 or a slow sustained release over hours. We can 00:12:25.610 --> 00:12:29.129 also identify potential problems. Like if the 00:12:29.129 --> 00:12:32.409 pill doesn't bring apart properly or if the drug 00:12:32.409 --> 00:12:35.269 particles aren't adequately exposed to the digestive 00:12:35.269 --> 00:12:38.669 fluids. This is really making me appreciate how 00:12:38.669 --> 00:12:42.289 much goes into designing an effective pill. It's 00:12:42.289 --> 00:12:44.409 complex. What are some of the factors that can 00:12:44.409 --> 00:12:47.360 affect how quickly a drug dissolves? Well, the 00:12:47.360 --> 00:12:50.059 drug's solubility is a big one. Think of trying 00:12:50.059 --> 00:12:53.179 to dissolve sugar in water. A highly soluble 00:12:53.179 --> 00:12:56.360 drug will dissolve quickly, while a poorly soluble 00:12:56.360 --> 00:12:58.639 one might need some help. So is that where those 00:12:58.639 --> 00:13:00.879 excipients, the inactive ingredients come in? 00:13:00.960 --> 00:13:03.240 Exactly. And they boost the solubility of a drug? 00:13:03.480 --> 00:13:06.139 Exactly. Excipients are the unsung heroes of 00:13:06.139 --> 00:13:09.759 drug formulation. Some act as solubilizers, helping 00:13:09.759 --> 00:13:12.080 the drug dissolve more readily in the digestive 00:13:12.080 --> 00:13:15.059 fluids. Others improve the way the drug particles 00:13:15.059 --> 00:13:17.039 interact with those fluids, making sure they 00:13:17.039 --> 00:13:20.360 get adequately wetted. And still others can modify 00:13:20.360 --> 00:13:22.740 the drug's release, creating a sustained release 00:13:22.740 --> 00:13:24.879 formulation that delivers the medication over 00:13:24.879 --> 00:13:27.360 a longer period. So it sounds like an intricate 00:13:27.360 --> 00:13:30.850 dance of chemistry and biology. It is. Carefully 00:13:30.850 --> 00:13:32.730 choreographed to get the drug where it needs 00:13:32.730 --> 00:13:35.590 to go. It truly is. And particle size also plays 00:13:35.590 --> 00:13:38.690 a role. OK. Imagine trying to dissolve a sugar 00:13:38.690 --> 00:13:42.350 cube versus granulated sugar. Right. The granulated 00:13:42.350 --> 00:13:44.570 sugar with its smaller particles and greater 00:13:44.570 --> 00:13:48.090 surface area will dissolve much faster. OK, that 00:13:48.090 --> 00:13:50.850 makes sense. So grinding a poorly soluble drug 00:13:50.850 --> 00:13:53.210 into a fine powder can help it dissolve more 00:13:53.210 --> 00:13:55.370 quickly. Exactly. And then there's this fascinating 00:13:55.370 --> 00:13:58.539 concept called polymorphism. Polymorphism. Some 00:13:58.539 --> 00:14:01.379 drugs can exist in different crystalline forms. 00:14:01.379 --> 00:14:04.960 OK. Kind of like how carbon can form both diamond 00:14:04.960 --> 00:14:07.120 and graphite. Interesting. And these different 00:14:07.120 --> 00:14:09.000 forms, even though they're chemically the same, 00:14:09.320 --> 00:14:12.620 can have different solubilities. Wow. I had no 00:14:12.620 --> 00:14:15.340 idea. It was so complex. So choosing the right 00:14:15.340 --> 00:14:18.220 crystalline form is crucial for optimizing dissolution. 00:14:18.409 --> 00:14:20.789 Absolutely. And it's this attention to detail, 00:14:21.029 --> 00:14:24.289 this understanding of the interplay between chemistry, 00:14:24.409 --> 00:14:27.570 biology, and engineering that allows us to create 00:14:27.570 --> 00:14:30.769 safe, effective, and reliable medications. You 00:14:30.769 --> 00:14:32.990 mentioned earlier that the formulation isn't 00:14:32.990 --> 00:14:35.419 static. Can you elaborate on that? Right. The 00:14:35.419 --> 00:14:38.440 formulation of a drug is not set in stone. OK. 00:14:38.580 --> 00:14:40.840 It often undergoes refinements and improvements 00:14:40.840 --> 00:14:42.899 as we gather more knowledge about the drug's 00:14:42.899 --> 00:14:45.679 behavior in the body. Sometimes we discover that 00:14:45.679 --> 00:14:48.120 a slight tweak in the formulation can significantly 00:14:48.120 --> 00:14:51.059 enhance its bioavailability or reduce side effects. 00:14:51.279 --> 00:14:53.340 A constant evolution. This is all incredibly 00:14:53.340 --> 00:14:55.879 insightful. Good. But I'm curious, are there 00:14:55.879 --> 00:14:58.440 certain challenges in drug development that are 00:14:58.440 --> 00:15:01.139 particularly difficult to overcome? Certainly, 00:15:01.240 --> 00:15:04.120 one of the biggest hurdles is developing drugs 00:15:04.120 --> 00:15:07.059 for diseases that affect the brain. Oh, the brain. 00:15:07.139 --> 00:15:09.200 The blood brain barrier, a protective shield 00:15:09.200 --> 00:15:11.539 around the brain, is incredibly effective at 00:15:11.539 --> 00:15:15.340 keeping out harmful substances. Right. But unfortunately, 00:15:15.580 --> 00:15:17.960 it also blocks many potential drugs from reaching 00:15:17.960 --> 00:15:19.840 their targets. So it's like trying to deliver 00:15:19.840 --> 00:15:22.639 a package to a high -security building. Yes. 00:15:22.840 --> 00:15:24.860 With a really strict doorman. That's a great 00:15:24.860 --> 00:15:26.820 way to put it. He's not letting anything in. 00:15:26.970 --> 00:15:29.789 And researchers are constantly working on new 00:15:29.789 --> 00:15:32.909 strategies to overcome this obstacle. One approach 00:15:32.909 --> 00:15:35.970 is to design drugs that are more lipophilic or 00:15:35.970 --> 00:15:38.970 fat -soluble, which allows them to slip through 00:15:38.970 --> 00:15:42.429 the barrier more easily. Another is to package 00:15:42.429 --> 00:15:46.850 drugs in nanoparticles, tiny delivery vehicles 00:15:46.850 --> 00:15:49.690 that can sneak past the defenses. That's amazing. 00:15:49.730 --> 00:15:52.309 It's like a microscopic Trojan horse. delivering 00:15:52.309 --> 00:15:54.549 the drug right to the target. Exactly. And there 00:15:54.549 --> 00:15:57.210 are many other innovative approaches being explored. 00:15:57.350 --> 00:15:59.690 Such as? Like temporarily disrupting the barrier 00:15:59.690 --> 00:16:02.409 with focused ultrasound. Oh, wow. Or designing 00:16:02.409 --> 00:16:04.669 drugs that can hitch a ride on existing transport 00:16:04.669 --> 00:16:06.669 systems that cross the barrier. It sounds like 00:16:06.669 --> 00:16:09.169 a constant game of scientific chess trying to 00:16:09.169 --> 00:16:12.090 outmaneuver the body's defenses. That's a perfect 00:16:12.090 --> 00:16:14.070 analogy. And another challenge is developing 00:16:14.070 --> 00:16:17.049 drugs for rare diseases. Rare diseases. These 00:16:17.049 --> 00:16:19.509 conditions often affect only a small number of 00:16:19.509 --> 00:16:22.539 people. OK. Making it difficult. to recruit patients 00:16:22.539 --> 00:16:26.019 for clinical trials and attract investment from 00:16:26.019 --> 00:16:28.039 pharmaceutical companies. I can see how that 00:16:28.039 --> 00:16:31.559 creates a difficult situation if fewer people 00:16:31.559 --> 00:16:34.519 have the disease. The potential market for a 00:16:34.519 --> 00:16:37.639 new drug is smaller, which might discourage investment. 00:16:37.720 --> 00:16:40.779 Right. But these patients still deserve effective 00:16:40.779 --> 00:16:43.669 treatments. Absolutely. And thankfully, there's 00:16:43.669 --> 00:16:46.490 been increasing recognition of the need to develop 00:16:46.490 --> 00:16:49.429 therapies for rare diseases. Governments and 00:16:49.429 --> 00:16:52.029 regulatory agencies are offering incentives to 00:16:52.029 --> 00:16:54.169 encourage research and development in this area. 00:16:54.350 --> 00:16:56.850 That's great. And patient advocacy groups are 00:16:56.850 --> 00:16:59.470 working tirelessly to raise awareness and funding. 00:16:59.750 --> 00:17:01.669 It's inspiring to see people coming together 00:17:01.669 --> 00:17:04.210 to address these challenges. But let's switch 00:17:04.210 --> 00:17:06.450 gears for a moment. Sure. And talk about a concept 00:17:06.450 --> 00:17:09.109 that often comes up in conversations about drug 00:17:09.109 --> 00:17:11.390 development. OK. The idea of a magic bullet. 00:17:11.470 --> 00:17:13.890 Is this a realistic goal or just a Hollywood 00:17:13.890 --> 00:17:17.109 fantasy? That's a great question. The magic bullet 00:17:17.109 --> 00:17:21.569 concept, a term coined over a century ago, envisions 00:17:21.569 --> 00:17:24.890 a drug that targets and destroys disease -causing 00:17:24.890 --> 00:17:28.190 agents with absolute precision, leaving healthy 00:17:28.190 --> 00:17:30.779 cells untouched. So it's like a guided missile 00:17:30.779 --> 00:17:32.599 that takes out the enemy without causing any 00:17:32.599 --> 00:17:35.339 collateral damage. That's the idea. OK. But the 00:17:35.339 --> 00:17:38.140 human body is incredibly complex. And even our 00:17:38.140 --> 00:17:41.460 most targeted therapies can have unintended consequences. 00:17:42.180 --> 00:17:44.359 We've made incredible progress in developing 00:17:44.359 --> 00:17:47.579 more precise treatments. But that perfect magic 00:17:47.579 --> 00:17:50.839 bullet with zero risk and absolute specificity 00:17:50.839 --> 00:17:53.440 remains elusive. So it's more about managing 00:17:53.440 --> 00:17:56.359 expectations. Well, we can strive for greater 00:17:56.359 --> 00:17:59.380 precision and fewer side effects. Yes, but achieving 00:17:59.380 --> 00:18:02.039 perfect targeting might be an unrealistic goal 00:18:02.039 --> 00:18:03.880 You've hit the nail on the head drug development 00:18:03.880 --> 00:18:07.660 is a delicate balancing act Weighing the potential 00:18:07.660 --> 00:18:09.839 benefits of a treatment against its inherent 00:18:09.839 --> 00:18:12.339 risks, right? And we're always striving to improve 00:18:12.339 --> 00:18:15.500 that balance to develop drugs that provide the 00:18:15.500 --> 00:18:19.099 most benefit with the least harm Well said this 00:18:19.099 --> 00:18:21.380 conversation has really opened my eyes to the 00:18:21.380 --> 00:18:24.220 complexities of drug development It's a fascinating 00:18:24.220 --> 00:18:26.579 field. It's inspiring to see how scientists are 00:18:26.579 --> 00:18:29.039 constantly pushing the boundaries, tackling these 00:18:29.039 --> 00:18:31.920 challenges head on. It's a truly remarkable field, 00:18:31.980 --> 00:18:34.779 and it's constantly evolving. Speaking of evolution, 00:18:35.079 --> 00:18:38.160 let's talk about some of the most promising areas 00:18:38.160 --> 00:18:41.940 of research, those areas where we might see breakthroughs 00:18:41.940 --> 00:18:44.960 in the coming years. Now you're talking, let's 00:18:44.960 --> 00:18:47.000 hear about those game changers. What's on the 00:18:47.000 --> 00:18:49.980 horizon? One area that holds immense potential 00:18:49.980 --> 00:18:53.720 is gene therapy. Gene therapy, OK. This revolutionary 00:18:53.720 --> 00:18:56.279 approach aims to treat diseases at their root 00:18:56.279 --> 00:19:00.220 by correcting faulty genes. Wow. So imagine being 00:19:00.220 --> 00:19:02.779 able to cure inherited disorders like cystic 00:19:02.779 --> 00:19:06.980 fibrosis or sickle cell anemia. By repairing 00:19:06.980 --> 00:19:09.180 the defective gene, it sounds like science fiction. 00:19:09.400 --> 00:19:11.000 Are we really at that point? We're getting there. 00:19:11.400 --> 00:19:13.339 Well, gene therapy is still in its early stages. 00:19:13.619 --> 00:19:16.299 There have been some remarkable successes, particularly 00:19:16.299 --> 00:19:18.700 in treating certain types of cancer and rare 00:19:18.700 --> 00:19:21.160 genetic diseases. That's amazing. But of course, 00:19:21.200 --> 00:19:23.460 there are challenges. Like what? Particularly 00:19:23.460 --> 00:19:26.059 ensuring the safety and long -term effectiveness 00:19:26.059 --> 00:19:29.039 of these therapies. I can imagine that manipulating 00:19:29.039 --> 00:19:32.099 genes comes with a whole new set of ethical and 00:19:32.099 --> 00:19:34.380 safety considerations. Absolutely. And that's 00:19:34.380 --> 00:19:37.000 why gene therapy research is conducted with extreme 00:19:37.000 --> 00:19:41.490 care and under strict regulatory But the potential 00:19:41.490 --> 00:19:44.809 benefits are so profound that this area of research 00:19:44.809 --> 00:19:47.250 is truly worth exploring. It's incredible to 00:19:47.250 --> 00:19:49.869 think about the possibilities. What else is out 00:19:49.869 --> 00:19:52.009 there on the cutting edge? Another promising 00:19:52.009 --> 00:19:55.589 area is immunotherapy. Immunotherapy. Which harnesses 00:19:55.589 --> 00:19:58.069 the power of the body's own immune system to 00:19:58.069 --> 00:20:00.859 fight disease. Wow. This approach has already 00:20:00.859 --> 00:20:02.980 shown remarkable success in treating certain 00:20:02.980 --> 00:20:06.259 cancers, and researchers are exploring its potential 00:20:06.259 --> 00:20:08.799 for other conditions like autoimmune diseases 00:20:08.799 --> 00:20:11.319 and infectious diseases. So it's like giving 00:20:11.319 --> 00:20:14.519 your body's natural defenses a supercharge, equipping 00:20:14.519 --> 00:20:16.500 them to better recognize and attack the enemy. 00:20:16.640 --> 00:20:18.839 That's a great way to put it, and there are many 00:20:18.839 --> 00:20:21.200 different types of immunotherapy being developed. 00:20:21.880 --> 00:20:24.799 Some... boosts the overall activity of the immune 00:20:24.799 --> 00:20:28.660 system, while others train specific immune cells 00:20:28.660 --> 00:20:32.400 to target and destroy diseased cells. It's mind 00:20:32.400 --> 00:20:33.980 -blowing and it sounds like we're moving towards 00:20:33.980 --> 00:20:37.119 a more personalized approach to medicine. Yes. 00:20:37.440 --> 00:20:39.720 Tailoring treatments to an individual's unique 00:20:39.720 --> 00:20:42.539 genetic and immunological profile. You're absolutely 00:20:42.539 --> 00:20:45.180 right. The future of drug development lies in 00:20:45.180 --> 00:20:48.259 precision medicine, where treatments are tailored 00:20:48.259 --> 00:20:50.980 to the individual patient, taking into account 00:20:50.980 --> 00:20:53.619 their specific needs and characteristics. And 00:20:53.619 --> 00:20:56.460 this is where advances in genomics, proteomics, 00:20:56.599 --> 00:20:59.119 and bioinformatics are playing a crucial role. 00:20:59.339 --> 00:21:01.799 We're gaining an unprecedented understanding 00:21:01.799 --> 00:21:05.180 of the molecular basis of disease, which is allowing 00:21:05.180 --> 00:21:08.519 us to develop more targeted and effective therapies. 00:21:08.759 --> 00:21:10.519 This is all so fascinating. It sounds like we're 00:21:10.519 --> 00:21:12.450 on the cusp of a a new era in medicine. It's 00:21:12.450 --> 00:21:14.650 very exciting. But I'm sure with all this progress, 00:21:14.869 --> 00:21:16.809 there are still challenges and setbacks along 00:21:16.809 --> 00:21:19.349 the way. Of course, drug development is a long 00:21:19.349 --> 00:21:22.150 and winding road. Right. Full of unexpected twists 00:21:22.150 --> 00:21:25.089 and turns. Not every promising lead will pan 00:21:25.089 --> 00:21:27.529 out. Of course. And setbacks are inevitable. 00:21:27.750 --> 00:21:30.470 That's true. But it's a journey driven by human 00:21:30.470 --> 00:21:33.849 ingenuity, perseverance, and a deep desire to 00:21:33.849 --> 00:21:37.150 improve human health. So true. And it's important 00:21:37.150 --> 00:21:40.170 to celebrate The success is while also learning 00:21:40.170 --> 00:21:42.529 from the failures and keep pushing forward. Exactly. 00:21:42.630 --> 00:21:44.410 And it's important to remember that drug development 00:21:44.410 --> 00:21:47.190 is a collaborative effort involving scientists 00:21:47.190 --> 00:21:50.450 from many different disciplines, regulatory agencies, 00:21:50.970 --> 00:21:53.529 pharmaceutical companies, and most importantly, 00:21:53.950 --> 00:21:56.109 patients themselves. It's a reminder that science 00:21:56.109 --> 00:21:59.039 is a human endeavor. It is. Driven by a shared 00:21:59.039 --> 00:22:01.519 desire to understand, to heal, and to improve 00:22:01.519 --> 00:22:04.380 the well -being of humankind. Well said. This 00:22:04.380 --> 00:22:06.480 has been an incredibly insightful conversation. 00:22:06.839 --> 00:22:08.420 And grand. I feel like I've gained a whole new 00:22:08.420 --> 00:22:10.960 appreciation for the complexities of drug development. 00:22:11.319 --> 00:22:13.559 Good. But before we wrap up this part of our 00:22:13.559 --> 00:22:16.319 deep dive, there's one thing I'm still a bit 00:22:16.319 --> 00:22:19.500 fuzzy on. Okay. How do scientists actually measure 00:22:19.500 --> 00:22:21.920 bioavailability? It seems like a tricky thing 00:22:21.920 --> 00:22:24.980 to pin down. It is tricky. Yeah. But thankfully, 00:22:25.299 --> 00:22:27.359 scientists have developed some clever methods 00:22:27.359 --> 00:22:30.000 to determine how much of a drug actually reaches 00:22:30.000 --> 00:22:33.460 the bloodstream. OK. One common approach is to 00:22:33.460 --> 00:22:36.059 compare the blood concentration time profiles 00:22:36.059 --> 00:22:39.940 of a drug after it's taken orally versus intravenously. 00:22:40.559 --> 00:22:43.660 OK. I'm intrigued why intravenous. Because with 00:22:43.660 --> 00:22:46.700 an intravenous injection, we know that 100 % 00:22:46.700 --> 00:22:49.500 of the drug enters the bloodstream immediately. 00:22:49.839 --> 00:22:52.509 Right. bypassing the absorption hurdles of the 00:22:52.509 --> 00:22:55.390 digestive system. It's like setting a benchmark, 00:22:55.549 --> 00:22:59.049 a perfect score for bioavailability. I see. So 00:22:59.049 --> 00:23:01.910 by comparing the oral profile to this intravenous 00:23:01.910 --> 00:23:04.910 standard, scientists can calculate the percentage 00:23:04.910 --> 00:23:07.470 of the oral dose that actually reaches the bloodstream. 00:23:07.869 --> 00:23:09.849 Precisely. And there's more to it than just the 00:23:09.849 --> 00:23:12.190 total amount absorbed. Oh, really? We also look 00:23:12.190 --> 00:23:14.970 at how quickly the drug is absorbed, how long 00:23:14.970 --> 00:23:18.390 it stays in the body, and what the peak concentration 00:23:18.390 --> 00:23:20.960 in the blood is. So it's not just about the quantity, 00:23:21.140 --> 00:23:23.079 but also about the timing and duration of the 00:23:23.079 --> 00:23:25.319 drug's presence in the bloodstream. Exactly. 00:23:25.359 --> 00:23:28.440 We use terms like Cmax. Tmax. Which refers to 00:23:28.440 --> 00:23:30.779 the maximum concentration of the drug in the 00:23:30.779 --> 00:23:34.259 blood. OK. And AUC, which stands for area under 00:23:34.259 --> 00:23:37.519 the curve. Right. And represents the total exposure 00:23:37.519 --> 00:23:39.990 to the drug over time. OK, it's all starting 00:23:39.990 --> 00:23:42.950 to make sense now. So by analyzing these parameters, 00:23:43.309 --> 00:23:45.650 scientists can fine tune a drug's formulation 00:23:45.650 --> 00:23:48.950 and dosing regimen to maximize its therapeutic 00:23:48.950 --> 00:23:51.190 effect. Precisely. It's all about finding that 00:23:51.190 --> 00:23:53.990 sweet spot where the drug delivers the most benefit 00:23:53.990 --> 00:23:57.869 with the least risk. And remember, bioavailability 00:23:57.869 --> 00:24:01.069 can vary significantly depending on the formulation 00:24:01.069 --> 00:24:04.069 and even individual factors like age, genetics, 00:24:04.150 --> 00:24:06.410 and what you've eaten recently. Wow. It really 00:24:06.410 --> 00:24:08.720 is a personalized journey. It's amazing. how 00:24:08.720 --> 00:24:11.500 much we've learned about drug development in 00:24:11.500 --> 00:24:13.980 just this deep dive. I know, right? From the 00:24:13.980 --> 00:24:16.880 initial spark of an idea all the way to the intricacies 00:24:16.880 --> 00:24:19.440 of bioavailability and the challenges of reaching 00:24:19.440 --> 00:24:21.460 those hard to treat areas like the brain. There's 00:24:21.460 --> 00:24:23.819 a lot to it. It's fascinating. It's been a fascinating 00:24:23.819 --> 00:24:25.680 journey so far, hasn't it? But we're not quite 00:24:25.680 --> 00:24:27.859 done yet. I know this is only part two. There's 00:24:27.859 --> 00:24:30.019 still so much more to explore. You're right. 00:24:30.119 --> 00:24:32.319 We've only scratched the surface of this incredible 00:24:32.319 --> 00:24:35.000 world. Stay tuned for part three of our deep 00:24:35.000 --> 00:24:37.640 dive. where we'll delve even deeper into the 00:24:37.640 --> 00:24:40.920 fascinating world of drug development. It's remarkable 00:24:40.920 --> 00:24:43.039 to consider that the journey of a new medicine 00:24:43.039 --> 00:24:45.740 doesn't truly end even after it's approved and 00:24:45.740 --> 00:24:47.440 available to patients. Yeah, you're right. We 00:24:47.440 --> 00:24:49.599 talked about post -marketing surveillance earlier, 00:24:49.640 --> 00:24:52.500 how drugs are continuously monitored for long 00:24:52.500 --> 00:24:55.220 -term effects and any rare side effects that 00:24:55.220 --> 00:24:58.740 might not have shown up in clinical trials. The 00:24:58.740 --> 00:25:02.019 scientific process never really stops always 00:25:02.019 --> 00:25:05.470 seeking more data. and refining our understanding. 00:25:05.849 --> 00:25:08.069 Precisely. And speaking of refining our understanding, 00:25:08.289 --> 00:25:10.269 I think it's worth circling back to the concept 00:25:10.269 --> 00:25:13.710 of bioavailability. It's such a fundamental aspect 00:25:13.710 --> 00:25:16.009 of drug development, and it ties together so 00:25:16.009 --> 00:25:18.009 many of the concepts we've been discussing. Yeah, 00:25:18.009 --> 00:25:19.609 you're right. It's fascinating how something 00:25:19.609 --> 00:25:22.369 as seemingly simple as swallowing a pill can 00:25:22.369 --> 00:25:24.630 be so complex when you look at it from a scientific 00:25:24.630 --> 00:25:27.710 perspective. I'm curious, are there any specific 00:25:27.710 --> 00:25:30.390 examples that really highlight the importance 00:25:30.390 --> 00:25:33.660 of bioavailability? Absolutely. One classic example 00:25:33.660 --> 00:25:36.160 involves grapefruit juice. And certain medications 00:25:36.160 --> 00:25:38.220 you might have heard that you shouldn't drink 00:25:38.220 --> 00:25:40.279 grapefruit juice while taking certain drugs. 00:25:40.599 --> 00:25:42.180 Oh, yeah. I remember reading something about 00:25:42.180 --> 00:25:45.640 grapefruit interfering with how the body metabolizes 00:25:45.640 --> 00:25:48.559 certain drugs. That's exactly right. Grapefruit 00:25:48.559 --> 00:25:50.960 contains compounds that can inhibit an enzyme 00:25:50.960 --> 00:25:53.099 in the liver that's responsible for breaking 00:25:53.099 --> 00:25:56.400 down many medications. And when this enzyme is 00:25:56.400 --> 00:25:58.880 inhibited, the drug levels in the bloodstream 00:25:58.880 --> 00:26:01.240 can increase dramatically. So instead of the 00:26:01.240 --> 00:26:03.480 drug being gradually metabolized, it's kind of 00:26:03.480 --> 00:26:05.640 hanging around longer than intended, leading 00:26:05.640 --> 00:26:08.279 to a higher concentration in the body. Precisely. 00:26:08.339 --> 00:26:11.099 It's as if you've taken a much larger dose of 00:26:11.099 --> 00:26:13.420 the drug than intended, which can lead to a higher 00:26:13.420 --> 00:26:16.200 risk of side effects. In some cases, it can even 00:26:16.200 --> 00:26:18.779 be dangerous. Wow, that's incredible. It really 00:26:18.779 --> 00:26:20.700 highlights how intricate the interplay between 00:26:20.700 --> 00:26:23.400 food drugs and our individual biology can be. 00:26:23.559 --> 00:26:25.900 It certainly does, and it underscores the importance 00:26:25.900 --> 00:26:28.920 of understanding bioavailability and how it can 00:26:28.920 --> 00:26:32.119 be influenced by a variety of factors. Another 00:26:32.119 --> 00:26:34.680 example involves differences in how individuals 00:26:34.680 --> 00:26:38.160 absorb and metabolize drugs. For example, some 00:26:38.160 --> 00:26:40.619 people are genetically predisposed to metabolize 00:26:40.619 --> 00:26:43.819 certain drugs more slowly than others. So even 00:26:43.819 --> 00:26:46.359 if two people take the same dose of a medication, 00:26:47.200 --> 00:26:49.700 their bodies might process it differently, leading 00:26:49.700 --> 00:26:51.619 to different levels of the drug in their systems. 00:26:51.849 --> 00:26:55.430 Exactly. And this is where the concept of personalized 00:26:55.430 --> 00:26:57.750 medicine comes into play by understanding an 00:26:57.750 --> 00:27:00.150 individual's genetic makeup, their lifestyle, 00:27:00.309 --> 00:27:03.089 and other factors. We can tailor their treatment 00:27:03.089 --> 00:27:05.829 to optimize the drug's effectiveness and minimize 00:27:05.829 --> 00:27:08.170 the risk of side effects. It's fascinating how 00:27:08.170 --> 00:27:10.750 drug development is becoming more and more individualized, 00:27:10.950 --> 00:27:12.890 moving away from the one -size -fits -all approach. 00:27:13.079 --> 00:27:15.680 It is, and this shift toward personalized medicine 00:27:15.680 --> 00:27:18.160 is driven by advances in fields like genomics 00:27:18.160 --> 00:27:21.059 and bioinformatics, which allow us to analyze 00:27:21.059 --> 00:27:23.160 an individual's genetic blueprint and predict 00:27:23.160 --> 00:27:25.299 how they might respond to certain medications. 00:27:25.720 --> 00:27:27.920 It's incredible to think about how far we've 00:27:27.920 --> 00:27:30.019 come in our understanding of drug development, 00:27:30.339 --> 00:27:32.940 from those early days of trial and error to the 00:27:32.940 --> 00:27:35.039 precision and personalization we're seeing today. 00:27:35.259 --> 00:27:37.220 It's truly remarkable, and it's important to 00:27:37.220 --> 00:27:39.900 remember that behind Every breakthrough, every 00:27:39.900 --> 00:27:42.980 new treatment, there's a team of dedicated scientists, 00:27:43.339 --> 00:27:45.799 researchers, clinicians, and patients who have 00:27:45.799 --> 00:27:48.319 contributed to this incredible journey. You're 00:27:48.319 --> 00:27:50.420 absolutely right. And as we wrap up this deep 00:27:50.420 --> 00:27:53.369 dive into the world of drug development. I want 00:27:53.369 --> 00:27:55.210 to thank you, our listeners, for joining us on 00:27:55.210 --> 00:27:58.289 this journey. We hope you've gained a new appreciation 00:27:58.289 --> 00:28:01.369 for the complexity, the challenges, and the incredible 00:28:01.369 --> 00:28:03.990 triumphs of this field. We encourage you to continue 00:28:03.990 --> 00:28:06.210 exploring to ask questions and to stay curious 00:28:06.210 --> 00:28:09.289 about the science that shapes our lives. Remember, 00:28:09.329 --> 00:28:11.750 knowledge is power, especially when it comes 00:28:11.750 --> 00:28:14.369 to our health. Well said, and until next time, 00:28:14.609 --> 00:28:16.670 keep those questions coming, and we'll do our 00:28:16.670 --> 00:28:18.930 best to delve deep and uncover the answers together.